Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henri Roche

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
La Revue Du Praticien|February 6, 2019
Breast cancer diagnostic assessmentFlorence Dalenc, Elvire Pons, Henri Roche
Bulletin Du Cancer|May 23, 2013
[Anticancer drug adherence]Fabien Despas, Henri Roche, Guy Laurent
Cancer|May 27, 2010
Systemic therapy of inflammatory breast cancer from high-dose chemotherapy to targeted therapies: the French experiencePatrice Viens, Carole Tarpin, Henri Roche, et al.
Cancer Control : Journal of the Moffitt Cancer Center|February 25, 2003
High-dose chemotherapy for breast cancer: the French PEGASE experienceHenri Roche, Patrice Viens, Pierre Biron, et al.
Breast Cancer Research and Treatment|November 10, 2010
Economic issues involved in integrating genomic testing into clinical care: the case of genomic testing to guide decision-making about chemotherapy for breast cancer patientsPatricia Marino, Carole Siani, François Bertucci, et al.
Oncology|January 12, 2008
A phase I dose-escalating and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancerJean Pierre Delord, Florence Dalenc, Frédéric Pinguet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2008
Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysisFabrice Andre, Kristine Broglio, Henri Roche, et al.
Clinical Breast Cancer|August 30, 2018
Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical TrialsHope S Rugo, Henri Roche, Eva Thomas, et al.
Cancer|October 21, 2006
Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 TrialCorinne Veyret, Christelle Levy, Philippe Chollet, et al.
Oncology|December 5, 2014
Neurotoxicity as a prognostic factor in patients with metastatic breast cancer treated with ixabepilone as a first-line therapyXavier Durando, Florence Dalenc, Catherine Abrial, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
La Revue Du Praticien|February 6, 2019
Breast cancer diagnostic assessmentFlorence Dalenc, Elvire Pons, Henri Roche
Bulletin Du Cancer|May 23, 2013
[Anticancer drug adherence]Fabien Despas, Henri Roche, Guy Laurent
Cancer|May 27, 2010
Systemic therapy of inflammatory breast cancer from high-dose chemotherapy to targeted therapies: the French experiencePatrice Viens, Carole Tarpin, Henri Roche, et al.
Cancer Control : Journal of the Moffitt Cancer Center|February 25, 2003
High-dose chemotherapy for breast cancer: the French PEGASE experienceHenri Roche, Patrice Viens, Pierre Biron, et al.
Breast Cancer Research and Treatment|November 10, 2010
Economic issues involved in integrating genomic testing into clinical care: the case of genomic testing to guide decision-making about chemotherapy for breast cancer patientsPatricia Marino, Carole Siani, François Bertucci, et al.
Oncology|January 12, 2008
A phase I dose-escalating and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancerJean Pierre Delord, Florence Dalenc, Frédéric Pinguet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2008
Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysisFabrice Andre, Kristine Broglio, Henri Roche, et al.
Clinical Breast Cancer|August 30, 2018
Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical TrialsHope S Rugo, Henri Roche, Eva Thomas, et al.
Cancer|October 21, 2006
Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 TrialCorinne Veyret, Christelle Levy, Philippe Chollet, et al.
Oncology|December 5, 2014
Neurotoxicity as a prognostic factor in patients with metastatic breast cancer treated with ixabepilone as a first-line therapyXavier Durando, Florence Dalenc, Catherine Abrial, et al.
Pageof 2